Fig. 1

a Clinical characteristics of MB patients (n = 90). Classification Molecular classification: WNT subgroup, SHH subgroup, Group 3 and Group 4 of patients. Gender (female and male). Age at diagnosis (below or above 3 years). Metastasis presence of metastasis at diagnosis (yes, no); Relapse presence of postoperative disease relapse (yes, no). Tumor resection (gross-total resection GTR; non-gross total resection non-GTR). Treatment treatment protocol (craniospinal radiotherapy plus carboplatin, ifosfamide, vincristine, etoposide; craniospinal radiotherapy plus CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea), cisplatin, vincristine; Baby POG – Pediatric Oncology Group). Death if patient died (yes, no). Institution institute where patients received treatment, Monosomy of chromosome 6 if patient bears this feature (yes, no), GLI2 Amplification if patients bears feature (yes, no), Isochromosome (17q) if patient bears feature (yes, no), Methylation Array 450 K Molecular assignment by methylation array of WNT (6), SHH (2), Group 3 (2) and Group 4 (1) samples. b Hierarchical unsupervised clustering of 92 primary MB into four molecular subgroups: SHH (green), WNT (purple), Group 3 (red) and Group 4 (blue). Pearson distance as Metric and average linkage as algorithm clustering. L1, L2, L3, L4 and L5 are represented as UW473, DAOY, UW402, UW228 and ONS-76 MB cell lines and “na” as samples tumors with unavailable data. c Copy number profile of sample 4 WNT subgroup (monosomy 6) (d) Copy number profile of sample 26 SHH Subgroup (Amplification of GLI2) (e) Copy number profile of sample 55 Group 3 (Isochromosome 17q)